Optimizing Chemotherapy of Pancreatic Acinar Cell Carcinoma: Our Experiences and Pooled Analysis of Literature
Open Access
- 1 January 2022
- journal article
- research article
- Published by SAGE Publications in Clinical Medicine Insights: Oncology
- Vol. 16
Abstract
Background: Pancreatic acinar cell carcinoma (PACC) is rare, and its appropriate treatment remains unknown. We aim to explore the characteristics and optimal treatment of it. Methods: The data on clinicopathologic characteristics, molecular alteration, treatment, and survival of patients diagnosed with PACC at the Sun Yat-sen University Cancer Center from 2005 to 2020 were collected. The optimal treatment was explored by co-analyzing our results and published literatures. Results: Twenty-two PACC patients were enrolled. Eight of 17 non-metastatic patients received adjuvant chemotherapy. The patients receiving fluoropyrimidine-based regimen (n = 3) had a better median disease-free survival (mDFS) than those with gemcitabine-based regimen (n = 5) (unreached vs 27 months). Eight metastatic patients received first-line chemotherapy. Four patients received second-line chemotherapy. The objective response rate (ORR) of the fluoropyrimidine-based regimen was 85.7% (6/7), much better than that of the gemcitabine-based regimen (0/5). One patient who had responded to the first-line FOLFIRINOX (5-fluorouracil + oxaliplatin + leucovorin + irinotecan) regimen received olaparib as maintenance treatment for 5 months with good tolerance. Thirty-one published literatures, with a total of 86 cases, were included in the co-analysis. The ORR of the first-line fluoropyrimidine-based regimen (n = 47) was higher than that of gemcitabine-based regimen (n = 39) (59.6% vs 15.3%, P < .001). Eight of 11 patients treated with the FOLFIRINOX regimen achieved partial response (PR). Conclusions: For patients with metastasis, a fluorouracil-based regimen such as FOLFIRINOX may be preferred, and maintenance treatment of poly ADP-ribose polymerase (PARP) inhibitors after effective platinum-containing treatment for breast cancer susceptibility gene (BRCA) mutation patients must be assessed.Keywords
All Related Versions
This publication has 51 references indexed in Scilit:
- Successful Salvage Chemotherapy with FOLFIRINOX for Recurrent Mixed Acinar Cell Carcinoma and Ductal Adenocarcinoma of the Pancreas in an Adolescent PatientCase Reports in Oncology, 2013
- Use of panitumumab in the treatment of acinar cell carcinoma of the pancreas: A case reportOncology Letters, 2012
- Acinar Cell Carcinoma of the Pancreas: New Genetic and Treatment Insights into a Rare MalignancyThe Oncologist, 2011
- FOLFOX regimen in pancreatic acinar cell carcinoma: Case report and review of the literatureActa Oncologica, 2011
- Four Cases of Pancreatic Acinar Cell Carcinoma Treated with Gemcitabine or S-1 as a Single AgentJapanese Journal of Clinical Oncology, 2009
- 672 patients with acinar cell carcinoma of the pancreas: a population-based comparison to pancreatic adenocarcinomaSurgery, 2008
- Current diagnosis and management of unusual pancreatic tumorsThe American Journal of Surgery, 2008
- Acinar Cell Carcinoma of the PancreasPancreas, 2007
- Genetic and Immunohistochemical Analysis of Pancreatic Acinar Cell CarcinomaThe American Journal of Pathology, 2002
- Acinar Cell Carcinoma of the PancreasAmerican Journal of Surgical Pathology, 1992